Dr. Nicholas P McAndrew, M.D.
Claim this profileUCLA / Jonsson Comprehensive Cancer Center
Studies Breast Cancer
Studies Cancer
2 reported clinical trials
6 drugs studied
Area of expertise
1Breast Cancer
ER positive
PR positive
HER2 negative
2Cancer
Affiliated Hospitals
Clinical Trials Nicholas P McAndrew, M.D. is currently running
Trastuzumab Deruxtecan + Anastrozole
for Breast Cancer
This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing the growth of tumors that need estrogen to grow. This study is evaluating how effective trastuzumab deruxtecan is at treating hormone receptor positive cancer cells that have low levels of HER2 expressed on them when given alone or in combination with anastrozole.
Recruiting1 award Phase 221 criteria
Triple Drug Therapy
for HER2 Positive Breast Cancer
This phase Ib/II trial studies the side effects and best dose of ribociclib, tucatinib, and trastuzumab for the treatment of HER2 positive breast cancer that has spread to other parts of the body (metastatic), and then compares the effect of ribociclib, tucatinib, trastuzumab with or without fulvestrant to docetaxel, carboplatin, trastuzumab, and pertuzumab (standard of care) for the treatment of early stage breast cancer before surgery (neoadjuvant therapy). Ribociclib and tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Pertuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Estrogen can cause the growth of breast tumor cells. Fulvestrant blocks the use of estrogen by the tumor cells. Chemotherapy drugs, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib, tucatinib, and trastuzumab with or without fulvestrant before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed.
Recruiting1 award Phase 1 & 220 criteria
More about Nicholas P McAndrew, M.D.
Clinical Trial Related3 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Nicholas P McAndrew, M.D. has experience with
- Ribociclib
- Trastuzumab
- Tucatinib
- Anastrozole
- Therapeutic Conventional Surgery
- Trastuzumab Deruxtecan
Breakdown of trials Nicholas P McAndrew, M.D. has run
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nicholas P McAndrew, M.D. specialize in?
Nicholas P McAndrew, M.D. focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved ER positive patients, or patients who are PR positive.
Is Nicholas P McAndrew, M.D. currently recruiting for clinical trials?
Yes, Nicholas P McAndrew, M.D. is currently recruiting for 2 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Nicholas P McAndrew, M.D. has studied deeply?
Yes, Nicholas P McAndrew, M.D. has studied treatments such as Ribociclib, Trastuzumab, Tucatinib.
What is the best way to schedule an appointment with Nicholas P McAndrew, M.D.?
Apply for one of the trials that Nicholas P McAndrew, M.D. is conducting.
What is the office address of Nicholas P McAndrew, M.D.?
The office of Nicholas P McAndrew, M.D. is located at: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California 90095 United States. This is the address for their practice at the UCLA / Jonsson Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.